or Try an Advanced Search...

    Nervous System Disorders Stocks List

    Symbol Grade Name % Change
    SAGE F Sage Therapeutics, Inc. -1.22
    IRWD F Ironwood Pharmaceuticals, Inc. -5.11
    TRVN F Trevena, Inc. 1.79
    PASG F Passage Bio, Inc. 4.34
    DRRX F DURECT Corporation -4.54
    BEAM D Beam Therapeutics Inc. -3.72
    ACAD C ACADIA Pharmaceuticals Inc. -0.55
    PRTC C PureTech Health plc 0.39
    VNDA C Vanda Pharmaceuticals Inc. 0.82
    SAVA C Cassava Sciences, Inc. 23.53
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic
    Related Stock Lists: Central Nervous System Disorders Biopharmaceutical Schizophrenia Alzheimer's Disease Chemical Compounds Chronic Pain Organic Compounds Pain Biology Biomarkers Biotechnology Cardiovascular Disease Chronic Disease Clinical Development Gastrointestinal Medication Opioids Parkinson's Disease Psychiatry Psychosis

    Related ETFs - A few ETFs which own one or more of the above listed Nervous System Disorders stocks.

    Symbol Grade Name Weight
    PSIL C AdvisorShares Psychedelics ETF 4.78
    BBP C BioShares Biotechnology Products Fund 1.62
    DEEP B Roundhill Acquirers Deep Value ETF 0.9
    QQQS C Invesco NASDAQ Future Gen 200 ETF 0.75
    BIS B ProShares UltraShort Nasdaq Biotechnology 0.72
    View all Nervous System Disorders ETFs...
    Compare ETFs
    Compare BBP to QQQS Compare DEEP to BIS Compare DEEP to QQQS

        Nervous System Disorders Stocks Recent News

        Date Stock Title
        Nov 21 ACAD Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
        Nov 21 SAGE Sage Therapeutics Drug's Failure in Huntington's 'Not Surprising,' RBC Says
        Nov 21 SAGE Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More
        Nov 21 SAGE Sage ends dalzanemdor development following Phase II trial failure
        Nov 21 SAGE SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study
        Nov 21 SAGE Sage raised to sector perform by RBC in wake of drug failure
        Nov 20 SAGE After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder
        Nov 20 SAGE Sage slips as Huntington’s Disease therapy fails in mid-stage trial
        Nov 20 PRTC PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors
        Nov 20 SAGE Sage’s string of research failures continues
        Nov 20 SAGE Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease
        Nov 19 SAGE CNS Drug Development: Same As It Ever Was
        Nov 18 SAVA Cassava taps Freda Nassif as chief commercial officer as simufilam Phase 3 readout nears
        Nov 18 SAVA Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer
        Nov 15 SAVA Cassava Sciences updates on Phase 3 Alzheimer’s trial ahead of key readout
        Nov 15 SAVA Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year?
        Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic
        Related Stock Lists: Central Nervous System Disorders Acute And Chronic Pain Acute Pain Adjunctive Therapy Analgesics Anticonvulsants Antidepressants Biopharmaceutical Cardiovascular Disease Cell Signaling Chronic Idiopathic Constipation Chronic Pain Clinical Development Constipation Digestive Diseases Drugs Gabaa Receptor Positive Allosteric Modulators Gastroenterology Gastrointestinal Gastrointestinal Disease
        Nervous System Disorders

        Nervous system disorders are conditions that affect the functioning of the brain, spinal cord, and nerves. These disorders can affect the way the body moves, senses, thinks, and behaves. Examples of nervous system disorders include Alzheimer's disease, epilepsy, Parkinson's disease, multiple sclerosis, stroke, and spinal cord injuries.

        Browse All Tags